AMARIN CORP PLC\UK Selling Expense
AMARIN CORP PLC\UK (AMRN) reported Selling Expense of $1.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingExpense · last filed 2026-07-29
- AMARIN CORP PLC\UK selling expense for the quarter ending 2026-06-30 was $1.78M, a 78.94% decline year-over-year.
- AMARIN CORP PLC\UK selling expense for the quarter ending 2026-03-31 was $2.55M, a 65.41% decline year-over-year.
- AMARIN CORP PLC\UK selling expense for the quarter ending 2025-12-31 was $2.93M, a 72.28% decline year-over-year.
- AMARIN CORP PLC\UK selling expense for the quarter ending 2025-09-30 was $2.72M, a 70.11% decline year-over-year.
- AMARIN CORP PLC\UK selling expense for fiscal 2025 was $21.51M, a 46.42% decline from fiscal 2024.
- AMARIN CORP PLC\UK selling expense for fiscal 2024 was $40.15M, a 29.86% decline from fiscal 2023.
- AMARIN CORP PLC\UK selling expense for fiscal 2023 was $57.24M, a 51.08% decline from fiscal 2022.
- AMARIN CORP PLC\UK selling expense for fiscal 2022 was $117.01M.
| Period end | Selling Expense 3 month | Selling Expense 6 month | Selling Expense 9 month | Selling Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.78M 10-Q · filed 2026-07-29 | $4.34M 10-Q · filed 2026-07-29 | $7.27M derived: sum of 3 quarters · filed 2026-07-29 | $9.99M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $2.55M 10-Q · filed 2026-04-29 | $5.48M derived: sum of 2 quarters · filed 2026-04-29 | $8.21M derived: sum of 3 quarters · filed 2026-04-29 | $16.68M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.65M derived: sum of 2 quarters · filed 2026-03-02 | $14.13M derived: sum of 3 quarters · filed 2026-07-29 | $21.51M 10-K · filed 2026-03-02 |
| 2025-09-30 | $2.72M 10-Q · filed 2025-10-29 | $11.20M derived: sum of 2 quarters · filed 2026-07-29 | $18.58M 10-Q · filed 2025-10-29 | $29.15M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $8.48M 10-Q · filed 2026-07-29 | $15.86M 10-Q · filed 2026-07-29 | $26.43M derived: sum of 3 quarters · filed 2026-07-29 | $35.54M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $7.38M 10-Q · filed 2026-04-29 | $17.95M derived: sum of 2 quarters · filed 2026-04-29 | $27.06M derived: sum of 3 quarters · filed 2026-04-29 | $37.28M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $10.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $19.68M derived: sum of 2 quarters · filed 2026-03-02 | $29.90M derived: sum of 3 quarters · filed 2026-03-02 | $40.15M 10-K · filed 2026-03-02 |
| 2024-09-30 | $9.11M 10-Q · filed 2025-10-29 | $19.33M derived: sum of 2 quarters · filed 2025-10-29 | $29.58M 10-Q · filed 2025-10-29 | |
| 2024-06-30 | $10.22M 10-Q · filed 2025-07-30 | $20.47M 10-Q · filed 2025-07-30 | ||
| 2024-03-31 | $10.25M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $57.24M 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $117.01M 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |